Yinhua CSI Innovative Drugs Industry ETF (159992) Rises 2.42%, Sees Share Growth of 54 Million Units Over the Past Two Weeks

NewTimeSpace News, as of 14:31 on May 11, 2026, Yinhua Innovative Drug ETF (159992) rose 2.42%, with its latest quoted price at 0.85 yuan. Looking at a longer timeframe, as of May 8, 2026, Yinhua Innovative Drug ETF gained 12.86% over the past year. (The stocks listed above are merely index constituents and do not constitute any specific recommendation.)

In terms of liquidity, Yinhua Innovative Drug ETF recorded an intraday turnover rate of 5.94%, with a trading volume of 912 million yuan. Over a longer horizon, as of May 8, the ETF's average daily turnover over the past month stood at 670 million yuan, ranking first among comparable funds.

Regarding scale, Yinhua Innovative Drug ETF's AUM increased by 33.5715 million yuan over the past two weeks, achieving significant growth, with the new scale increment ranking 3/7 among comparable funds. (Data source: Wind)

In terms of share size, Yinhua Innovative Drug ETF's share count increased by 54.00 million units over the past two weeks, achieving significant growth, with the new share increment ranking 3/7 among comparable funds. (Data source: Wind)

In terms of capital inflows, the latest net inflow for Yinhua Innovative Drug ETF was 67.1419 million yuan. Looking at a longer timeframe, over the past seven trading days, the total net inflow amounted to 29.8076 million yuan. (Data source: Wind)

Data shows that leveraged funds continue to position themselves. The net margin purchase amount for Yinhua Innovative Drug ETF on the previous trading day reached 15.5026 million yuan, and the latest margin balance stood at 610 million yuan. (Data source: Wind)

As of May 8, Yinhua Innovative Drug ETF's net value increased by 15.44% over the past two years. In terms of return capability, as of May 8, 2026, since its inception, the ETF achieved a highest single-month return of 22.79%, a longest consecutive gaining streak of four months with a cumulative gain of 53.27%, and an average return of 6.47% during up months. As of May 8, 2026, the ETF's annualized excess return over its benchmark over the past two years was 0.60%.

In terms of drawdown, as of May 8, 2026, Yinhua Innovative Drug ETF's relative drawdown versus its benchmark since the beginning of the year was 0.18%.

In terms of fees, Yinhua Innovative Drug ETF has a management fee rate of 0.50% and a custody fee rate of 0.05%.

In terms of tracking accuracy, as of May 8, 2026, Yinhua Innovative Drug ETF's one-month tracking error was 0.009%, indicating relatively high tracking precision among comparable funds.

From a valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI Innovative Drug Industry Index, which Yinhua Innovative Drug ETF tracks, is only 49.19 times, placing it at the 17.62nd percentile over the past year—meaning the valuation is lower than that of over 82.38% of the time in the past year, indicating a historically low level.

Yinhua Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main business involves innovative drug research and development as index constituents, in order to reflect the overall performance of listed company securities in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.